[p53 and hematologic malignancies].
Alterations in the p53 gene are less common in hematological malignancies (10 to 15%) than in solid tumors, and usually consist in point mutations, which can be readily detected using SSCP or ICC. In most cases (except in non-Hodgkin's lymphoma) there is a close correlation between point mutations and a positive ICC. In myelodysplastic syndromes, acute myeloid leukemia, chronic myeloid leukemia, and chronic lymphoid leukemia, point mutations affecting one allele are accompanied with deletion of the other allele. The complete absence of the p53 gene in these conditions probably explains the poor prognosis and resistance to chemotherapy in these patients. In contrast, in the L3 form of acute lymphoid leukemia and Burkitt's non-Hodgkin's lymphoma, punctual mutations are common (30%) and rarely accompanied with deletion of 17p. These data confirm the key role of p53 in the induction of apoptosis after chemotherapy and support the need for developing tools for transferring the p53 gene into malignant cells with the goal of restoring chemosensitivity.
Preudhomme
C
C
Laboratoire d'Hématologie A, CHRU Hôpital Calmette, Lille, France.
Fenaux
P
P
D016158:Genes, p53; D019337:Hematologic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007938:Leukemia / Q000235:genetics; D008223:Lymphoma / Q000235:genetics; D009190:Myelodysplastic Syndromes / Q000235:genetics; D009367:Neoplasm Staging; D017354:Point Mutation; D011379:Prognosis
p53 et hémopathies malignes.